雷替曲塞治疗结直肠癌的临床应用

国际肿瘤学杂志››2013,Vol. 40››Issue (12): 933-935.doi:10.3760/cma.j.issn.1673-422X.2013.12.017

雷替曲塞治疗结直肠癌的临床应用

彭登付, 王勇, 胡冰

230001 合肥，安徽医科大学附属省立医院肿瘤化疗科

出版日期:2013-12-10发布日期:2013-12-26
通讯作者:胡冰 E-mail:hubin3756@sina.com
基金资助:

安徽省自然科学基金（12070403084）

Clinical applications of raltitrexed in colorectal cancer

PENG Deng-Fu, WANG Yong, HU Bing

Department of Chemotherapy, Affiliated Provincial Hospital, Anhui Medial University, Hefei 230001, China

Online:2013-12-10Published:2013-12-26
Contact:HU Bing E-mail:hubin3756@sina.com

摘要/Abstract

摘要：雷替曲塞是一种新型的特异性胸苷酸合成酶（TS）抑制剂，在临床研究中表现出显著的抗肿瘤活性。国内外研究显示，雷替曲塞治疗结直肠癌疗效确切，耐受性较好，并且使用方便，可广泛应用于结直肠癌的临床治疗。

彭登付, 王勇, 胡冰. 雷替曲塞治疗结直肠癌的临床应用[J]. 国际肿瘤学杂志, 2013, 40(12): 933-935.

PENG Deng-Fu, WANG Yong, HU Bing. Clinical applications of raltitrexed in colorectal cancer[J]. Journal of International Oncology, 2013, 40(12): 933-935.

［1］ International Agency for Research on Cancer. World cancer report 2008. Lyon: WHO, 2008: 374. ［2］ Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5fluorouraeil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma?. Clin Colorectal Cancer, 2009, 8(4): 231234. ［3］ Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma. Expert Rev Anticancer Ther, 2011, 11(10): 14811490. ［4］ Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorinmodulated bolus 5fluorouracil: results from the randomised phase Ⅲ PanEuropean Trial in Adjuvant Colon Cancer 01 (PETACC1). Eur J cancer, 2008, 44(15): 22042211. ［5］ Deboever G, Hitrop N, Cool M, et al. Alternative treatment options in colorectal cancer patients with 5fluorouracil or capecitabineinduced cardiotoxicity. Chin colorectal Cancer, 2013, 12(1): 814. ［6］ Viéitez JM, Valladares M, Peláez I, et al. A randomized phase Ⅱ study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. Invest New Drugs, 2011, 29(5): 10381044. ［7］余嘉文. 雷替曲塞单药二线治疗晚期大肠癌疗效观察. 中国现代药物应用, 2012, 6(4): 1819. ［8］ Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs, 2010, 21(6): 656661. ［9］王佳蕾, 李进, 秦叔逵, 等. 雷替曲塞或5FU/CF联合奥沙利铂治疗局部晚期或复发转移性结直肠癌多中心、随机、对照Ⅲ期临床试验. 临床肿瘤学杂志, 2012, 17(1): 611. ［10］ Gravalos C, Salut A, Sevilla I, et al. A randomized phase Ⅱ study to compare FOLFOX4 versus TOMOX as firstline chemotherapy for advanced colorectal cancer. Clin Transl Oncol, 2012, 14(8): 606612. ［11］ Paiva CE, Paiva BS, Garita R, et al. Acute coronary syndrome associated with continuous 5Fluorouracil infusion in a patient with metastatic colorectal cancera case report with a discussion on this clinical dilemma. Gastrointest Cancer, 2009, 40(34): 133137. ［12］ Geurs F, Vandewaeter S, Ponette S, et al. Successful and welltolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer. J Gastrointest Cancer, 2008, 39(14): 2628. ［13］ Aparicio J, de las Peas R, Vicent JM, et al. Multicenter phase Ⅰ study of irinotecan plus raltitrexed in patients with 5fluorouracilrefractory advanced colorectal cancer. Oncology, 2002, 63(1): 4247. ［14］ Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase Ⅱ trial evaluating a threeweekly schedule of irinotecan plus raltitrexed in patients with 5fluorouracil refractory advanced colorectal Cancer. Ann Oncol, 2003, 14(7): 11211125. ［15］谢达成, 李宁, 王静珏, 等. 雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察. 临床肿瘤学杂志, 2013, 18(2): 140143. ［16］ Vakhahova JV, Semenov NN, Dobrova NV, et al. Clinical study of combined use of raltitrexed and xeloda as firstline treatment for patients with metastasizing colorectal cancel. Bull Exp Biol Med, 2008, 145(2): 24925l. ［17］ Garavatta L, Picardi V, Padula GD, et al. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase Ⅱ study. Acta Oncologica, 2011, 50(8): 11511157. ［18］ Valentini V, Coco C, Minsky BD, et al. Randomized, multicenter, phase Ⅱb study of preoperative chemoradiotherapy in T3 middistal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5fluorouracil + radiotherapy. Int J Radiat Oncol Biol Phys, 2008, 70(2): 403412. ［19］ Wilson KS, Malfair Taylor SC. Raltitrexed: optimism and reality. Expert Opin Drug Metab Toxicol, 2009, 5(11): 14471454. ［20］ Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer, 2013, 49(10): 23032310.

[1]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[6]	刘德宝, 孙子雯, 鲁守堂, 徐海东.ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[7]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[8]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[9]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[10]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺.结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[11]	徐良富, 李袁飞.MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[12]	刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[13]	耿睿, 马俊强, 郭强, 牛钊峰.老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[14]	陶红, 殷红, 罗宏, 陶佳瑜.靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[15]	王熙, 吴川清.结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.